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26.1 Migraine 
Migraine affects 10-15% of the population, being more common in females, and with 
peak prevalence between 35 and 45 years of age. Migraine symptoms comprise a 
unilateral (sometimes contralateral), localized, throbbing headache that may persist for 
72 hours, often accompanied by nausea and vomiting, photophobia (light sensitivity) 
and phonophobia (sound sensitivity). Roughly 20% of sufferers experience an “aura” 
preceding the headache. The aura may involve visual disturbances such as scintillating 
zig-zag lines, scotoma (blind spot), or blurred vision, accompanied by transient aphasia, 
chills, vertigo, or unilateral parasthesia (numbness or weakness). 
 
The actual cause of migraine is unknown, and it can be triggered by almost anything, but 
most commonly psychosocial, environmental, neurochemical and neuroendocrine 
changes. Known triggers in susceptible individuals include cheese, chocolate, alcohol, 
chemicals, sunlight, hormones, and the contraceptive pill. 
 
26.2 Pathogenesis of Migraine 
While the biochemical initiators of migraine or underlying abnormality that predisposes 
some individuals are not well known, migraine is now recognized to have neural and 
vascular involvement, highlighting the important interaction between nerves and the 
cerebral vessels. The headache originates from pain-sensitive extracerebral structures 
such as the meninges and large arteries, which are innervated by nociceptive sensory 
nerves of the trigeminal system, paving the way for the neurogenic inflammation. 
Another important phenomenon that occurs in migraine is cortical spreading 
depression, thought to explain the aura or increased susceptibility to migraine. 
 
26.3 Cortical Spreading Depression 
Cortical spreading depression can be viewed as a wave of transient neural inhibition 
(spontaneous and evoked activity) that progresses slowly over the cortex at 2-6 mm per 
minute. This wave of depression is preceded by a transient wave of intense excitation 
associated with very high extracellular K+ and reduced blood flow. Although the trigger 
of excitability is not known, accumulation of extracellular K+ due to enhanced excitation 
depolarises adjacent neurons, causing the phenomenon to spread. Changes in blood 
flow or spreading excitation and depression may initiate the headache. Moreover, the 
localised spreading depression may activate the trigeminal nucleus caudalis (of the 
central pain pathway), sensitising the central pain pathway. 
 
26.4 Neurogenic Inflammation Theory 
The trigeminocerebrovascular system comprises the ophthalmic trigeminal ganglia, the 
cells of which innervate major vessels regulating cerebral blood flow, smaller meningeal 
(especially dura mater) vessels, the meninges, and centrally projecting sensory fibres 
synapsing on to the trigeminal nucleus caudalis in the caudal brainstem and cervical 
spinal cord. The pain sensitive structures include the blood vessels and meninges, thus 
trigeminal fibres afford a conduit for nociceptive information originating in the blood 
vessels and meninges to the central nervous system.  
 
Stimulation of the trigeminal fibres, which are nociceptive C fibres, causes pain directly, 
as well as release of neuropeptides such as calcitonin gene-related peptide (CGRP), 
substance P and neurokinin, and also nitric oxide, leading to vasodilation. Following 
sufficient activation resulting perhaps from cortical excitation, blood vessel constriction 
or lowered sensitisation threshold to certain stimuli, inflammatory events occur 
including plasma extravasation (leakage from vessels), platelet activation, 5-HT 
secretion, mast cell degranulation and secretion of bradykinin, histamine and 
prostaglandins. This provides a localised “inflammatory soup” that continues to 
sensitise and activate the C fibres, contributing to neurogenic inflammation of the dura 
mater and blood vessels. 
 
CGRP release is thought to regulate normal blood flow, since vasoconstriction triggers 
antidromic (feed forward) release of CGRP from trigeminal nerves, leading to 
vasodilation. Interestingly, CGRP is released in correspondence with the pain of 
migraine and its concentration has been shown to correlate with headache intensity. 
CGRP is also a marker of trigeminal activity. Thus, migraine may involve a lowered 
threshold of trigeminal activation, and hypersensitivity to local neuropeptide release, 
including CGRP, which not only causes vasodilation in pain-sensitive structures, but 
causes chemical irritation and may lower the pain threshold to previously innocuous 
stimuli.  
 
Figure 26.1 schematically depicts the trigeminocerebrovascular pathways and 
highlights the important neuropeptides and neurotransmitters involved in these 
pathways. 
 
 
 
Figure 26.1: Schematic depiction of the trigeminocerebrovascular pathway highlighting the role of 
neurogenic inflammation in the pathogenesis of migraine and the neurpetides involved. Location 
of 5-HT receptors is also shown, highlighting their crucial role in migraine and its treatment. 
(Copyright The University of Sydney, Tina Hinton) 
 
26.5 Role for 5-HT in Migraine 
5-HT is thought to be intrinsically linked to migraine. Evidence shows a sharp increase 
in urinary 5-HIAA (the catabolic product of 5-HT) and a fall in blood 5-HT concentration 
during a migraine attack. Moreover, migraine sufferers display perturbed 5-HT 
metabolism and transmission. 5-HT1B and 5-HT2 receptors are found on extracerebral 
blood vessels. Stimulation of 5-HT2 receptors indirectly causes vasodilation via release 
of nitric oxide, while activation of 5-HT1B receptors leads to vasoconstriction. As 
highlighted in Figure 1, 5HT1B, 1D and 1F receptors, located on trigeminal nerve fibres and 
the trigeminal nucleus caudalis, become important regulators of the 
trigeminocerebrovascular system, since their activation would have an inhibitory effect 
on neurotransmission. 
 
26.5 Acute Treatment of Migraine 
It is important to distinguish between drugs that are used to treat acute migraine 
attacks, and drugs used in migraine prophylaxis, required for cases of at least two 
migraine attacks per month. 
 
Acute attacks are treated with non-steroidal anti-inflammatory drugs (NSAIDs) such as 
aspirin and paracetamol, ergotamines, and more commonly, triptans. NSAIDs are 
usually effective for mild attacks and when taken shortly after the onset of pain.   
 
For over 70 years ergotamines such as ergotamine tartrate and dihydroergotamine 
were the classical treatment for migraine. These drugs can relieve the pain of migraine 
even when taken more than four hours after onset. Ergotamines are partial agonists at 
5-HT1D receptors, thus blocking trigeminal nerve transmission, however they act at 
many additional monoamine receptors, including 5-HT1B, 5-HT2, dopamine D1 and D2, 
noradrenergic α1 and α2 receptors. Subsequently, their usefulness is limited by their 
propensity to cause vasoconstriction, including of the coronary vessels, and foetal 
damage. They also cause nausea and vomiting due to activation of area postrema. 
 
Triptans have become first line treatment for acute severe migraine, replacing 
ergotamines. A number of triptans are available, including sumaptriptan (the 
prototype), zolmitriptan, almotriptan and naratriptan. The differences between these 
drugs lie in their plasma half life and time to peak plasma levels. Moreover, sumatriptan 
does not cross the blood brain barrier, while the other drugs do. Up to 80% of patients 
respond to triptans within two hours of administration, and up to 40% experience 
headache recurrence within 24 hours of initial relief. 
 
All triptans are 5-HT1B/1D agonists, and their effects on migraine are numerous. 
Activation of these receptors on trigeminal ganglia and trigeminal nucleus caudalis cells 
inhibits transmission of nociceptive information from the blood vessels and meninges 
to the brainstem and central pain pathways. Additionally, stimulation of presynaptic 5-
HT1B/1D autoreceptors on trigeminal cell bodies inhibits release of neuropeptides from 
trigeminal ganglia cells, thus reducing neurogenic inflammation. Moreover, on 
extracerebral blood vessels, activation of 5HT1B/1D receptors causes vasoconstriction, 
thus facilitating restoration of normal vascular tone. Finally, triptans relieve the nausea 
associated with migraine. One drawback, however, is their ability to cause 
vasoconstriction of coronary arteries via 5-HT1B receptors, thus they are 
contraindicated in cardiovascular disease. 
 
26.6 Prophylactic Treatment of Migraine 
Drugs used in prophylactic treatment of migraine include β-adrenoceptor antagonists, 
5-HT2 receptor antagonists, anticonvulsants and calcium channel antagonists. The type 
of prophylactic drug is chosen on the basis of factors such as contraindications, co-
morbid conditions and tolerability. Even when used, only 50% of sufferers can expect a 
reduction in migraine frequency. 
 
-adrenoceptor antagonists such as propranolol and metoprolol have been used 
successfully in the prophylactic treatment of migraine. The mechanism of prophylaxis is 
unknown, but it may be due to vasoconstrictor effects. These drugs are contraindicated 
in respiratory diseases such as asthma, and side effects include fatigue and 
bronchoconstriction. 
 
5-HT2 antagonists such as pizotifen, cyproheptadine and methysergide act by 
preventing 5-HT2 receptor-induced vasodilation, secondary to nitric oxide production, 
and consequent inflammation. Adverse effects include weight gain and methysergide is 
now rarely used owing to the risk of retroperitoneal fibrosis and renal failure with long-
term use. 
 
Anticonvulsants such as sodium valproate, gabapentin and topiramate are thought to 
prevent migraine by increasing inhibitory GABAergic and Ca2+ channel activity, thus 
reducing cortical excitability and possibly the threshold for triggering migraine attacks. 
These drugs may reduce cortical spreading excitation, hence depression, and trigeminal 
neurotransmission, however they are teratogens thus their use is excluded during 
pregnancy and lactation. 
 
Finally, calcium channel antagonists like nifedipine and verapamil have shown some 
efficacy, and act to decrease cellular excitability by reducing Ca2+ entry into cells. 
 
The need remains for improved drugs, with greater selectivity and fewer side effects, for 
treatment of migraine. Drugs that act selectively on 5-HT1D/1F receptors would remove 
5-HT1B-induced constriction of coronary and cerebral arteries. The role of CGRP in 
regulation of vascular tone and in the pathogenesis of migraine is being increasingly 
recognised, and CGRP antagonists such as olcegepant.  
 
